{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:00:42Z","timestamp":1783404042509,"version":"3.54.6"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T00:00:00Z","timestamp":1354147200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"DOI":"10.1038\/cddis.2012.175","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T11:11:16Z","timestamp":1354187476000},"page":"e436-e436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1"],"prefix":"10.1038","volume":"3","author":[{"given":"N","family":"Amodio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M T","family":"Di Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Foresta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Lionetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Leotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Gull\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Pitari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Agosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Fulciniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Misso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ferrarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N C","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K C","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,29]]},"reference":[{"key":"BFcddis2012175_CR1","first-page":"7","volume":"43","author":"D Pattanayak","year":"2005","unstructured":"Pattanayak D, Agarwal S, Sumathi S, Chakrabarti SK, Naik PS, Khurana SM . Small but mighty RNA-mediated interference in plants. Indian J Exp Biol 2005; 43: 7\u201324.","journal-title":"Indian J Exp Biol"},{"key":"BFcddis2012175_CR2","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.1016\/j.febslet.2005.08.071","volume":"579","author":"G Hutvagner","year":"2005","unstructured":"Hutvagner G, Small RNA . asymmetry in RNAi: function in RISC assembly and gene regulation. FEBS Lett 2005; 579: 5850\u20135857.","journal-title":"FEBS Lett"},{"key":"BFcddis2012175_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nature03315","volume":"433","author":"LP Lim","year":"2005","unstructured":"Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769\u2013773.","journal-title":"Nature"},{"key":"BFcddis2012175_CR4","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.cell.2006.07.031","volume":"126","author":"KC Miranda","year":"2006","unstructured":"Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006; 126: 1203\u20131217.","journal-title":"Cell"},{"key":"BFcddis2012175_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.gde.2005.08.005","volume":"15","author":"EA Miska","year":"2005","unstructured":"Miska EA . How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005; 15: 563\u2013568.","journal-title":"Curr Opin Genet Dev"},{"key":"BFcddis2012175_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/10428190802535114","volume":"50","author":"M Fabbri","year":"2009","unstructured":"Fabbri M, Croce CM, Calin GA . MicroRNAs in the ontogeny of leukemias and lymphomas. Leuk Lymphoma 2009; 50: 160\u2013170.","journal-title":"Leuk Lymphoma"},{"key":"BFcddis2012175_CR7","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2353\/ajpath.2009.080794","volume":"174","author":"R Visone","year":"2009","unstructured":"Visone R, Croce CM . MiRNAs and cancer. Am J Pathol 2009; 174: 1131\u20131138.","journal-title":"Am J Pathol"},{"key":"BFcddis2012175_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1997","volume":"6","author":"GA Calin","year":"2006","unstructured":"Calin GA, Croce CM . MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857\u2013866.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2012175_CR9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nature04303","volume":"438","author":"J Krutzfeldt","year":"2005","unstructured":"Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. Silencing of microRNAs in vivo with \u2018antagomirs\u2019. Nature 2005; 438: 685\u2013689.","journal-title":"Nature"},{"key":"BFcddis2012175_CR10","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1056\/NEJMcibr060065","volume":"354","author":"MP Czech","year":"2006","unstructured":"Czech MP . MicroRNAs as therapeutic targets. N Engl J Med 2006; 354: 1194\u20131195.","journal-title":"N Engl J Med"},{"key":"BFcddis2012175_CR11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nrg2634","volume":"10","author":"CM Croce","year":"2009","unstructured":"Croce CM . Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704\u2013714.","journal-title":"Nat Rev Genet"},{"key":"BFcddis2012175_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrc1840","volume":"6","author":"A Esquela-Kerscher","year":"2006","unstructured":"Esquela-Kerscher A, Slack FJ . Oncomirs\u2014microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259\u2013269.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2012175_CR13","doi-asserted-by":"publisher","first-page":"5923","DOI":"10.1158\/0008-5472.CAN-10-0655","volume":"70","author":"JF Wiggins","year":"2010","unstructured":"Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010; 70: 5923\u20135930.","journal-title":"Cancer Res"},{"key":"BFcddis2012175_CR14","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.6004\/jnccn.2011.0095","volume":"9","author":"KC Anderson","year":"2011","unstructured":"Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD et al. Multiple myeloma. J Natl Compr Canc Netw 2011; 9: 1146\u20131183.","journal-title":"J Natl Compr Canc Netw"},{"key":"BFcddis2012175_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev-pathol-011110-130249","volume":"6","author":"KC Anderson","year":"2011","unstructured":"Anderson KC, Carrasco RD . Pathogenesis of myeloma. Annu Rev Pathol 2011; 6: 249\u2013274.","journal-title":"Annu Rev Pathol"},{"key":"BFcddis2012175_CR16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2174\/156800912802429300","volume":"12","author":"M Rossi","year":"2012","unstructured":"Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, Grimaldi A et al. Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug Targets 2012; 12: 757\u2013767.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFcddis2012175_CR17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/nrc952","volume":"2","author":"T Hideshima","year":"2002","unstructured":"Hideshima T, Anderson KC . Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2: 927\u2013937.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2012175_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S0037-1963(01)90017-4","volume":"38","author":"B Barlogie","year":"2001","unstructured":"Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A et al. Thalidomide in the management of multiple myeloma. Semin Hematol 2001; 38: 250\u2013259.","journal-title":"Semin Hematol"},{"key":"BFcddis2012175_CR19","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487\u20132498.","journal-title":"N Engl J Med"},{"key":"BFcddis2012175_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1053\/j.seminhematol.2003.09.005","volume":"40","author":"B Barlogie","year":"2003","unstructured":"Barlogie B . Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Semin Hematol 2003; 40: 33\u201338.","journal-title":"Semin Hematol"},{"key":"BFcddis2012175_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","volume":"54","author":"A Jemal","year":"2004","unstructured":"Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. Cancer statistics 2004 CA Cancer J Clin 2004; 54: 8\u201329.","journal-title":"CA Cancer J Clin"},{"key":"BFcddis2012175_CR22","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.1158\/1078-0432.CCR-09-1483","volume":"15","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z et al. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 2009; 15: 7144\u20137152.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2012175_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","volume":"114","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009; 114: 371\u2013379.","journal-title":"Blood"},{"key":"BFcddis2012175_CR24","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/leu.2008.81","volume":"22","author":"MA Shammas","year":"2008","unstructured":"Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 2008; 22: 1410\u20131418.","journal-title":"Leukemia"},{"key":"BFcddis2012175_CR25","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1158\/1078-0432.CCR-04-2611","volume":"11","author":"P Tassone","year":"2005","unstructured":"Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clin Cancer Res 2005; 11: 4251\u20134258.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2012175_CR26","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.1158\/1078-0432.CCR-12-1708","volume":"18","author":"MT Di Martino","year":"2012","unstructured":"Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR et al. Synthetic miR-34a mimics as a novel therapeutic agent for Multiple Myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012; 18: 6260\u20136270.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2012175_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2174\/156800912802429274","volume":"12","author":"M Lionetti","year":"2012","unstructured":"Lionetti M, Agnelli L, Lombardi L, Tassone P, Neri A . MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets 2012; 12: 823\u2013837.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFcddis2012175_CR28","doi-asserted-by":"publisher","first-page":"838","DOI":"10.2174\/156800912802429355","volume":"12","author":"P Tagliaferri","year":"2012","unstructured":"Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A et al. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 2012; 12: 838\u2013846.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFcddis2012175_CR29","first-page":"1930","volume":"88","author":"MM Le Beau","year":"1996","unstructured":"Le Beau MM, Espinosa R, Davis EM, Eisenbart JD, Larson RA, Green ED . Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996; 88: 1930\u20131935.","journal-title":"Blood"},{"key":"BFcddis2012175_CR30","doi-asserted-by":"publisher","first-page":"11590","DOI":"10.1158\/0008-5472.CAN-06-3613","volume":"66","author":"Y Pekarsky","year":"2006","unstructured":"Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006; 66: 11590\u201311593.","journal-title":"Cancer Res"},{"key":"BFcddis2012175_CR31","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.1038\/sj.onc.1210436","volume":"26","author":"JL Mott","year":"2007","unstructured":"Mott JL, Kobayashi S, Bronk SF, Gores GJ . mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26: 6133\u20136140.","journal-title":"Oncogene"},{"key":"BFcddis2012175_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.bbrc.2011.09.063","volume":"414","author":"YK Zhang","year":"2011","unstructured":"Zhang YK, Wang H, Leng Y, Li ZL, Yang YF, Xiao FJ et al. Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1. Biochem Biophys Res Commun 2011; 414: 233\u2013239.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcddis2012175_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nsmb.1533","volume":"16","author":"SY Park","year":"2009","unstructured":"Park SY, Lee JH, Ha M, Nam JW, Kim VN . miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009; 16: 23\u201329.","journal-title":"Nat Struct Mol Biol"},{"key":"BFcddis2012175_CR34","doi-asserted-by":"publisher","first-page":"15805","DOI":"10.1073\/pnas.0707628104","volume":"104","author":"M Fabbri","year":"2007","unstructured":"Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104: 15805\u201315810.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2012175_CR35","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.1073\/pnas.0801130105","volume":"105","author":"S Sengupta","year":"2008","unstructured":"Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 2008; 105: 5874\u20135878.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2012175_CR36","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.1182\/blood-2009-03-211938","volume":"114","author":"R Garzon","year":"2009","unstructured":"Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009; 114: 5331\u20135341.","journal-title":"Blood"},{"key":"BFcddis2012175_CR37","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/jcb.22630","volume":"110","author":"JL Mott","year":"2010","unstructured":"Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, Fernandez-Zapico ME . Transcriptional suppression of mir-29b-1\/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem 2010; 110: 1155\u20131164.","journal-title":"J Cell Biochem"},{"key":"BFcddis2012175_CR38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2008.10.006","volume":"14","author":"H Wang","year":"2008","unstructured":"Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008; 14: 369\u2013381.","journal-title":"Cancer Cell"},{"key":"BFcddis2012175_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1006\/excr.2000.5129","volume":"264","author":"L Zheng","year":"2001","unstructured":"Zheng L, Lee WH . The retinoblastoma gene: a prototypic and multifunctional tumor suppressor. Exp Cell Res 2001; 264: 2\u201318.","journal-title":"Exp Cell Res"},{"key":"BFcddis2012175_CR40","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1158\/1078-0432.CCR-11-1036","volume":"17","author":"M Fulciniti","year":"2011","unstructured":"Fulciniti M, Amin S, Nanjappa P, Rodig S, Prabhala R, Li C et al. Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res 2011; 17: 6500\u20136509.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2012175_CR41","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.molcel.2007.05.018","volume":"26","author":"J Tsang","year":"2007","unstructured":"Tsang J, Zhu J, van Oudenaarden A . MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell 2007; 26: 753\u2013767.","journal-title":"Mol Cell"},{"key":"BFcddis2012175_CR42","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1172\/JCI114110","volume":"83","author":"R Ray","year":"1989","unstructured":"Ray R, Snyder RC, Thomas S, Koller CA, Miller DM . Mithramycin blocks protein binding and function of the SV40 early promoter. J Clin Invest 1989; 83: 2003\u20132007.","journal-title":"J Clin Invest"},{"key":"BFcddis2012175_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrd1279","volume":"3","author":"M Karin","year":"2004","unstructured":"Karin M, Yamamoto Y, Wang QM . The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17\u201326.","journal-title":"Nat Rev Drug Discov"},{"key":"BFcddis2012175_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ccr.2010.03.008","volume":"17","author":"S Liu","year":"2010","unstructured":"Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ et al. Sp1\/NFkappaB\/HDAC\/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 2010; 17: 333\u2013347.","journal-title":"Cancer Cell"},{"key":"BFcddis2012175_CR45","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1182\/blood-2009-07-235663","volume":"116","author":"J Kikuchi","year":"2010","unstructured":"Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010; 116: 406\u2013417.","journal-title":"Blood"},{"key":"BFcddis2012175_CR46","doi-asserted-by":"publisher","first-page":"6345","DOI":"10.1200\/JCO.2005.05.024","volume":"23","author":"T Hideshima","year":"2005","unstructured":"Hideshima T, Chauhan D, Richardson P, Anderson KC . Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol 2005; 23: 6345\u20136350.","journal-title":"J Clin Oncol"},{"key":"BFcddis2012175_CR47","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1182\/blood.V98.9.2853","volume":"98","author":"J Hsu","year":"2001","unstructured":"Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001; 98: 2853\u20132855.","journal-title":"Blood"},{"key":"BFcddis2012175_CR48","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ng1536","volume":"37","author":"A Krek","year":"2005","unstructured":"Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495\u2013500.","journal-title":"Nat Genet"},{"key":"BFcddis2012175_CR49","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0092-8674(03)01018-3","volume":"115","author":"BP Lewis","year":"2003","unstructured":"Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB . Prediction of mammalian microRNA targets. Cell 2003; 115: 787\u2013798.","journal-title":"Cell"},{"key":"BFcddis2012175_CR50","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1182\/blood-2007-08-110171","volume":"111","author":"S Liu","year":"2008","unstructured":"Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1\/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008; 111: 2364\u20132373.","journal-title":"Blood"},{"key":"BFcddis2012175_CR51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2165\/00003088-200948030-00006","volume":"48","author":"DI Quinn","year":"2009","unstructured":"Quinn DI, Nemunaitis J, Fuloria J, Britten CD, Gabrail N, Yee L et al. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet 2009; 48: 199\u2013209.","journal-title":"Clin Pharmacokinet"},{"key":"BFcddis2012175_CR52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/1078-0432.CCR-11-0853","volume":"18","author":"SM Molineaux","year":"2012","unstructured":"Molineaux SM . Molecular pathways: targeting proteasomal protein degradation in cancer. Clin Cancer Res 2012; 18: 15\u201320.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2012175_CR53","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","volume":"114","author":"T Hideshima","year":"2009","unstructured":"Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009; 114: 1046\u20131052.","journal-title":"Blood"},{"key":"BFcddis2012175_CR54","doi-asserted-by":"publisher","first-page":"648","DOI":"10.4161\/cbt.8.7.7968","volume":"8","author":"P Tassone","year":"2009","unstructured":"Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T et al. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 2009; 8: 648\u2013653.","journal-title":"Cancer Biol Ther"},{"key":"BFcddis2012175_CR55","doi-asserted-by":"crossref","unstructured":"Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK et al. Canonical and non canonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood 2012 ; [e-pub ahead of print].","DOI":"10.1182\/blood-2011-07-368142"},{"key":"BFcddis2012175_CR56","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/gcc.20660","volume":"48","author":"M Lionetti","year":"2009","unstructured":"Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K et al. Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer 2009; 48: 521\u2013531.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFcddis2012175_CR57","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.2353\/ajpath.2010.091075","volume":"177","author":"N Amodio","year":"2010","unstructured":"Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, Franco R et al. Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am J Pathol 2010; 177: 2622\u20132634.","journal-title":"Am J Pathol"},{"key":"BFcddis2012175_CR58","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402\u2013408.","journal-title":"Methods"}],"container-title":["Cell Death & Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cddis2012175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cddis2012175","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2012175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:47:04Z","timestamp":1672962424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2012175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,29]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11]]}},"alternative-id":["BFcddis2012175"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2012.175","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,29]]},"assertion":[{"value":"28 August 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}